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INTRODUCTION
Asthma is a chronic inflammatory disease of the airways
inducing a reversible airway obstruction, characterized by
recurrent episodes of cough, chest tightness, breathlessness,
and wheezing (1).
Direct measurement of indices of airway inflammation was
only possible by postmortem examination (2, 3), broncho-
scopic biopsy (4-6), or bronchoalveolar lavage (BAL) (7-9).
These invasive procedures are not suitable for monitoring
inflammation in clinical practice. A non-invasive method
has been developed using sputum induced by inhalation of
hypertonic saline to quantify and characterize inflammatory
cells. Examination of sputum selected from saliva, use of
dithiothreitol to disperse the mucus, and use of cytospins
collectively provide a direct research tool in measuring acti-
vation markers, inflammatory mediators, and cellular func-
tions pertinent to asthma pathogenesis (10). Sputum induc-
tion is not only non-invasive and easily repeated but also
yields samples more concentrated airway secretions than
those obtained by bronchoscopy (11). Recently, induction of
sputum is revealed to be safe even in patients with severe
asthma (12).
Hypertonic saline aerosols are being used increasingly for
bronchial provocation testing (13-15). Airway responsive-
ness to hypertonic saline is positively related to the number
of peripheral blood basophils, eosinophils and monocytes
(16). Many authors (17, 18) have reported the high levels of
eosinophil cationic protein (ECP) and IL-5 in sputum of
asthmatic patients, which correlated with the severity of
asthma in other report (19).
The aims of this study were to assess the response to chal-
lenge with 3% hypertonic saline administered via a ultra-
sonic nebulizer in patients with asthma, and to evaluate
relationship between % fall of forced expiratory volume in
one second (FEV1) during induction of sputum (osmotic
airway hyperresponsiveness: osmotic AHR) and biochemi-
cal markers of sputum supernatant.
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Relationship Between Sputum Inflammatory Markers and Osmotic 
Airway Hyperresponsiveness During Induction of Sputum in Asthmatic 
Patients 
Hypertonic saline aerosols are being used increasingly for bronchial provocation
testing and induction of sputum. The aims of this study were to assess the
response to challenge with 3% hypertonic saline administered via a ultrasonic
nebulizer in patients with asthma, and to evaluate relationship between % fall of
FEV1 during induction of sputum (osmotic airway hyperresponsiveness; osmotic
AHR) and biochemical markers of induced sputum. We investigated changes in
FEV1 in response to inhaling ultrasonically nebulized 3% saline in 25 patients
with asthma and 10 control subjects. FEV1 was measured before, during, and
after induction of sputum. We used fluoroimmunoassay to detect eosinophil
cationic protein (ECP), immunohistochemical staining to detect EG2+ (secretory
form of ECP) eosinophils, and a sandwich ELISA to detect interleukin (IL)-5.
Protein concentration was determined by using bicinchoninic acid protein assay
reagent. Asthmatics, compared with controls, had significantly higher osmotic
AHR. Moderate to severe asthmatics had significantly higher osmotic AHR com-
pared to mild asthmatics. Osmotic AHR was significantly correlated with the pro-
portion of eosinophils, the levels of ECP, EG2+ eosinophils, IL-5, and proteins.
These data suggest that osmotic AHR is closely related to the clinical status and
biochemical markers of sputum supernatant in asthmatic patients. 
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MATERIALS AND METHODS
Subjects
Twenty-five patients with asthma and ten control sub-
jects were enrolled in this study (Table 1). Control subjects,
who volunteered for this study, had no history of respiratory
symptoms, and had FEV1>75% predicted, a ratio of FEV1
to forced vital capacity (FVC)>75%, and had a normal
methacholine airway responsiveness [provocation concentra-
tion of methacholine producing a 20% fall of FEV1
(PC20)>16 mg]. The diagnosis of asthma was established in
each patient by symptoms of recurrent episodic wheezing,
cough, and/or dyspnea, accompanied either by metha-
choline airway hyperresponsiveness or by a significant im-
provement of FEV1 (15%) following anti-asthma therapy.
No subject had respiratory infection for 4 weeks prior to the
study. Seonam University Hospital committee approved this
study, and all subjects signed the informed consent forms.
Study design
On the first visit, a questionnaire for symptoms and med-
ications was given and a spirometry was performed in each
patient. Then, induced sputum was collected, and skin
prick test and methacholine provocation test was done.
Clinical severity of asthma was classified according to the
method of Expert Panel Report 2 (including symptoms,
nighttime symptoms, and lung function (1). A person blind
to the clinical characteristics of the subjects performed all
measurements in sputum.
Spirometry was performed according to American Tho-
racic Society standards (20) using SensorMedics 2200
spirometer (Cardiopulmonary Care CompanyTM, Yorba
Linda, California). Methacholine challenge tests were car-
ried out by a modification of the method described by Chai
et al. (21) and the results were expressed as PC20 in non-
cumulative units.
Allergy skin prick tests were performed using 55 com-
mon allergen extracts. The wheal size was read 15 min later
and scored as follows: 0=no different from control, += 1-2
mm larger than control, ++=3-5 mm larger than control,
+++=6-8 mm larger than control, ++++=>8 mm larger
than control. The total number of+’ s was added. Atopy was
defined as atopy score>1+.
Osmotic AHR measurement during sputum induction
The sputum induction was performed by a modification of
the method described by Fahy et al. (22). All subjects were
premedicated with inhaled salbutamol 2-puff (200  g). Sub-
jects inhaled 3% hypertonic saline solution aerosols generat-
ed by a ultrasonic nebulizer (NE-U03, OMRON Co.,
Tokyo, Japan) with a maximum output of 0.15-0.3 mL/min
and mass median aerodynamic diameter of 4.5  m. Hyper-
tonic saline was inhaled for 15-20 min to induce 2cc volume
of sputum. The fall of FEV1 from FEV1 after inhalation of
short acting  2 agonist was measured before, during, and
after induction of sputum. Subjects were asked to rinse their
mouth and blow the nose to minimize contamination with
saliva and postnasal drip. They were encouraged to cough
deeply and frequently during hypertonic saline inhalation.
They were instructed to cough out the sputum into a sterile
plastic container.  The volumes of samples and the duration
of sputum induction were recorded. Sputum induction was
stopped in subjects with a fall of the FEV1≥15%.
Sputum processing
Sputum was selected from saliva and processed within 2
hr. The modified method (22) of sputum examination
described by Popov et al. (23) was used. Briefly, sputum was
treated by adding equal volumes of 0.1% dithiothreitol
(Sputalysin 10%; Gibco BRL, U.S.A.) followed by equal
volumes of Dulbecco’ s phosphate-buffered saline. The sam-
ple was then mixed gently and placed in a shaking water
bath at 37℃ for 15 min to ensure complete homogeniza-
tion. The sample was removed from the water bath periodi-
cally for further brief gentle mixing. The suspension was fil-
tered through gauze (1-mm pore size), the filtrate was cen-
trifuged at 1,500 rpm for 10 min, and the supernatant was
aspirated and stored in Eppendorf tubes at -70℃ for later
assay. The cell pellet was resuspended in 1 mL of Dulbecco’ s
phosphate-buffered saline, and total non-squamous cells
were counted in a modified Neubauer hemocytometer. The
cell suspension was adjusted to 0.5×10
5/mL then 50  L of
cell suspension was placed into cups of Sakura cytocen-
trifuge (Model CF-127, Tokyo, Japan), and two coded
cytospins were prepared at 600 rpm at 5 min, air-dried, and
stained by Diff-Quick (Kookje Scientific Products, Japan)
stain. Other two slides prepared for immunohistochemistry
were air-dried for 10 min, fixed in 0.25% formalin for 5
Subjects (n) 10 7 18
Age (yr) 33±4.5 38.2±5.2 42.6±2.8
Sex (M/F) 8/2 4/3 10/8
Atopy (n) 3 2 3
Smoker (ex) 2 (0) 2 (2) 2 (2)
PC20 (mg/mL) >16 1.33±0.85 1.84±0.67
FEV1 (% pred.) 92.6±1.0* 84.7±2.9 48.8±3.7
�
FVC (% pred.) 86.5±3.9 89.5±2.5 75.2±1.9
FEV1/FVC (%) 90.1±1.3* 92.4±3.8 57.4±2.6
�
Control subjects 
Table 1. Characteristics of subjects 
Asthmatics
mild  moderate to severe
Data are shown as mean±SEM. PC20: provocation concentration of
methacholine producing a 20% fall of FEV1. *p<0.01, compared with
asthmatics; 
� p<0.01, compared with mild asthmatics Sputum Inflammatory Markers and Osmotic Airway Hyperresponsiveness  413
min at 4℃, wrapped in pairs in foil, and stored at -70℃.
Cell differentials of 400 non-squamous cells were performed
in Diff-Quick stained slides by two investigators who were
not informed with the subject’ s history and the results were
expressed as percentage of the total non-squamous cell
count.
ECP and IL-5 measurements
The concentration of ECP in thawed supernatant was
determined using fluoroimmunoassay (UniCAP system).
IL-5 was measured by quantitative sandwich enzyme
immunoassay (QuantikineTM; R&D Systems, Inc., MN), as
described by Dickason (24). Samples were analyzed in
duplicate. The limit of detection for ECP and IL-5 assays
were 2.0  g/L and 3 pg/mL, respectively.
Immunohistochemistry for EG2
Immunohistochemistry was performed on sputum cytos-
pin slides with Probe On Plus slide (Fisher Scientific, Pitts-
burgh, PA). All steps of the staining procedure were done at
50℃ in microprobe system taking advantage of capillary
gap action (25) produced by two approximated Probe On
Plus slides. The primary antibody was applied for 15 min
with anti-EG2 antibody (secretory form of ECP, a gift from
Pharmacia Diagnostics, Uppsala, Sweden). Antigen/anti-
body complexes were detected with a goat anti-mouse IgG
(Sigma, St. Louis, MO) for 10 min followed by avidin-alka-
line phosphatase (Dako) (26) for 12 min after blocking
endogenous alkaline phosphatase activity in Redusol
(Biomed, Foster City, CA) for 5 min. The chromogen reac-
tion consisted of Fast Red TR Salt (Research Genetics,
Huntsville, AL) for 10 min followed by 30 sec of hema-
toxylin. EG2 antibodies were diluted in primary antibody
diluent (Research Genetics, Huntsville, AL) at a final con-
centration of 5  g/mL. Positive controls for EG2 consisted
of known positive samples were included in each staining.
Negative controls were established by staining without the
primary antibody. All slides were examined using standard
light microscopy by two observers, who scored percentage
of positive eosinophils over total non-squamous cells. Inten-
sity of staining reaction was not quantified.
Protein determination
Protein concentration was determined according to the
method by Smith et al. (27) using bicinchoninic acid pro-
tein assay reagent (Pierce, Rockford, U.S.A.) with bovine
serum albumin as a standard.
Statistical analysis
All data were analyzed using the SPSS version 7.5 for
Windows. Data are expressed as mean±SEM. Comparisons
of variables were performed using Mann-Whitney U test.
Spearman’ s correlations were used to assess relationships
between variables. A p-value of <0.05 was considered sig-
nificant.
RESULTS
Subject characteristics are given in Table 1. Asthmatic
patients had significantly lower FEV1, FEV1/FVC than con-
trol subjects. Moderate to severe asthmatic patients had sig-
nificantly lower FEV1, and FEV1/FVC than mild asthmatic
patients.
Osmotic airway hyperresponsiveness
Twenty-five sputum samples from asthmatics and ten
sputum samples from control subjects were analyzed. The
subjects experienced salty sense in 25 sputum induction tri-
als, chest tightness in three, and dyspnea in two. Mean
duration of induction was 15.6 min (range 5-30 min) in
asthmatic patients and 19.6 min (range 9-28 min) in con-
trol subjects. During sputum induction, there were falls of
FEV1≥15% after hypertonic saline inhalation for 5 min
and 9 min in two asthmatics, which required additional
inhalations of salbutamol aerosols. The maximal fall in
FEV1 from baseline during the hypertonic saline inhalation
was significantly greater in the asthmatics than in the con-
trol subjects (5.2±0.6% vs 1.5±0.9%, p<0.05, Fig. 1).
Osmotic AHR was significantly greater in moderate to
severe asthmatics than that in mild asthmatics (7.4±1.1%
vs 1.7±0.4%, p<0.01, Fig. 1).
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Fig. 1. Comparisons of osmotic AHR between control subjects
and asthmatic patients, and between mild and moderate to
severe asthmatic patients. Horizontal bars indicate mean values.414 A.S. Jang, I.-S. Choi
Correlations of osmotic AHR with biochemical mark-
ers and clinical parameters
Results of sputum eosinophils, EG2+ eosinophils, ECP,
and IL-5 analysis are given in Table 2. Each of these mea-
surements had an inverse relationship with FEV1 and FEV1/
FVC (Table 3). Inhalation of hypertonic saline aerosols for
sputum induction caused a fall in FEV1 in asthmatics even
after the premedication with inhaled salbutamol. Because of
the influence of premedication on the fall of FEV1, airway
responsiveness to hypertonic saline could not be fully exam-
ined. However, these partially blocked responses to osmotic
challenge showed a significant relationship with the propor-
tions of eosinophils and the levels of ECP (Fig. 2), EG2+
eosinophils, and IL-5 (Fig. 3). No correlation was noted bet-
ween osmotic AHR and atopy score or methacholine-AHR. 
DISCUSSION
In this study, we found that the fall of FEV1 during spu-
tum induction was closely related to the clinical status and
biochemical markers of sputum supernatant in patients
with asthma.
Recently, an examination of sputum induced by inhala-
tion of hypertonic saline has been introduced and it is
known to be a valuable and reproducible method in evalu-
ating eosinophilic asthmatic inflammation (1, 5, 10, 11,
28). Induced sputum separated from saliva for the indices
measured in asthmatic subjects is comparable with lower
respiratory secretions expectorated spontaneously and has
the advantage of better cell viability (29). Examination of
sputum selected from saliva, use of dithiothreitol to disperse
the mucus, and use of cytospins collectively provide a direct
and non-invasive research tool in measuring activation
markers, inflammatory mediators, and cellular functions
pertinent to asthma pathogenesis (10).
Hypertonic saline aerosols are being used increasingly for
bronchial provocation testing and induction of sputum in
patients with asthma (12, 13, 15). Bronchial provocation
tests using pharmacological agents such as methacholine or
histamine are used in epidemiological studies to identify
asthma despite recognition of limitations in specificity, pos-
itive predictive value, and availability of reagents. Hyper-
tonic saline bronchial challenge, although less sensitive than
pharmacological challenges, is reportedly highly specific in
diagnosing current asthma (12). A 4.5% hypertonic saline
Eosinophils (%) 1.7±0.27 6.4±1.2 40.9±5.8*
,�
EG2+cells (%) 0.3±0.04 2.7±1.02 35.5±5.6*
,�
ECP ( g/mL) 154.6±47.4 210.1±52.0 1470.0±251.5*
,�
IL-5 (pg/mL) 0±00 ±0 34.1±9.2*
,�
Control subjects 
Table 2. Biochemical markers in sputum
Asthmatics
mild  moderate to severe
All data are shown as mean±SEM; *p<0.01, compared with control
subjects; 
� p<0.05, compared with mild asthmatics; 
� p<0.01, com-
pared with mild asthmatics
FEV1 -0.489
� -0.489* -0.606
� -0.361*
FEV1/FVC -0.608
� -0.658
� -0.592
� -0.329*
MPC20 -0.063 -0.033 -0.150 -0.321
Atopy score -0.042 -0.079 0.125 -0.030
Table 3. Correlations (rs) of clinical findings with respective
biochemical sputum markers
Eosinophils (%) EG2 (%) ECP ( g/L) IL-5 (pg/mL)
rs, Spearman rank correlation coefficient; MPC20, Methacholine PC20.
*p<0.05, 
� p<0.01.
100
90
80
70
60
50
40
30
20
10
0
3500
3000
2500
2000
1500
1000
500
0
E
o
s
i
n
o
p
h
i
l
s
 
(
%
)
E
C
P
 
(
g
/
L
)
0 5 10 15 20
Osmotic AHR (%)
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challenge shows sensitivity and specificity similar to those
of standardized exercise challenge and pharmacologic chal-
lenges and even a higher sensitivity than cold air hyperven-
tilation and distilled water in identifying asthma.
Measurement of responsiveness to hypertonic saline may
be of value as an objective marker for studies to compare
prevalences of bronchial hyperresponsiveness and of asthma
over time (30). Hypertonic saline responsiveness bears a clos-
er relationship to the severity of exercise-induced asthma
symptoms than the non-specific bronchial hyperresponsive-
ness measured by histamine or methacholine reactivity (15).
Airway responsiveness to hypertonic saline is positively
related to the number of peripheral blood basophils, eosino-
phils, and monocytes (16). The present study using this
new non-invasive method showed that asthmatic patients,
compared with control subjects, had significantly higher
osmotic AHR, eosinophils (%), EG2+ eosinophils (%), lev-
els of ECP, and proteins in the induced sputum. In addi-
tion, we found that biochemical markers of eosinophils in
induced sputum in asthmatic patients were correlated with
osmotic AHR. But osmotic AHR was similar between in
mild asthmatics and controls. Further study will be needed
to clarify the role of hypertonic saline sputum induction in
large number of patients and controls.
Several investigators (17, 18) have reported the high lev-
els of ECP and IL-5 in sputum of patients with asthma.
These correlated with the severity of asthma (19). In this
study, moderate to severe asthmatic patients showed signifi-
cantly higher levels of eosinophil activation markers than
mild asthmatic patients. FEV1 and FEV1/FVC had a signifi-
cant relationship with these markers. The increase of inflam-
matory cells associated with increased expression of activa-
tion markers for lymphocytes and for eosinophil secretion is
found even in stable asthma and the associations between
these cell types, their activation status, and bronchial respon-
siveness have been suggested (31). In the present study, the
proportion of eosinophils and biochemical markers were
negatively correlated with severity of airway obstruction
(FEV1 and FEV1/FVC).
de la Fuente et al. (14) reported that induction of sputum
by hypertonic saline is a safe technique even in patients
with severe asthma. In this study, we found two patients
with severe asthma who had falls of FEV1≥15%, which
required additional inhalations of salbutamol aerosols dur-
ing sputum induction. Wong et al. (32) reported that pul-
monary function should be assessed regularly during spu-
tum induction in asthmatic subjects to monitor excessive
bronchoconstriction.
There are two limitations in this study. One is the use of a
bronchodilator prior to the hypertonic saline inhalation, for
safety, which might have minimized any changes in FEV1.
The other is that the amount of hypertonic saline inhaled
varied slightly depending on the ability to obtain sputum.
It is impossible to quantitate even partially airway hyperre-
sponsiveness when the intensity of the stimulus is different
from one patient to another. This is a major limitation in
this study.
In summary, we found that osmotic AHR was closely
related to the clinical status and biochemical markers of
sputum supernatant in asthmatic patients. Examination of
sputum induced by hypertonic saline is a safe method to
evaluate airway inflammation.
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